284 related articles for article (PubMed ID: 34268531)
21. Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real-life.
Asselah T; Loureiro D; Le Gal F; Narguet S; Brichler S; Bouton V; Abazid M; Boyer N; Giuly N; Gerber A; Tout I; Maylin S; Bed CM; Marcellin P; Castelnau C; Gordien E; Mansouri A
Liver Int; 2021 Jul; 41(7):1509-1517. PubMed ID: 33999515
[TBL] [Abstract][Full Text] [Related]
22. Treatment of hepatitis delta and HIV infection.
Soriano V; de Mendoza C; Treviño A; Ramos-Rincón JM; Moreno-Torres V; Corral O; Barreiro P
Liver Int; 2023 Aug; 43 Suppl 1():108-115. PubMed ID: 35748639
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Glebe D; Baringhaus KH; Geyer J
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921515
[TBL] [Abstract][Full Text] [Related]
24. Ergosterol peroxide blocks HDV infection as a novel entry inhibitor by targeting human NTCP receptor.
Chiou WC; Lyu YS; Hsia TL; Chen JC; Lin LC; Chang MF; Hsu MS; Huang C
Biomed Pharmacother; 2024 Jan; 170():116077. PubMed ID: 38154274
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis delta and HIV infection.
Soriano V; Sherman KE; Barreiro P
AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
[TBL] [Abstract][Full Text] [Related]
26. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection.
Sandmann L; Wedemeyer H
Clin Liver Dis; 2021 Nov; 25(4):831-839. PubMed ID: 34593156
[TBL] [Abstract][Full Text] [Related]
27. Bulevirtide: First Approval.
Kang C; Syed YY
Drugs; 2020 Oct; 80(15):1601-1605. PubMed ID: 32926353
[TBL] [Abstract][Full Text] [Related]
28. Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy.
Soriano V; Moreno-Torres V; Treviño A; Corral O; de Mendoza C
Drug Des Devel Ther; 2023; 17():155-166. PubMed ID: 36712949
[TBL] [Abstract][Full Text] [Related]
29. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies.
Lampertico P; Roulot D; Wedemeyer H
J Hepatol; 2022 Nov; 77(5):1422-1430. PubMed ID: 35752223
[TBL] [Abstract][Full Text] [Related]
30. Strategies to inhibit entry of HBV and HDV into hepatocytes.
Urban S; Bartenschlager R; Kubitz R; Zoulim F
Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
[TBL] [Abstract][Full Text] [Related]
31. Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Degasperi E; Anolli MP; Lampertico P
Liver Int; 2023 Aug; 43 Suppl 1():80-86. PubMed ID: 35942695
[TBL] [Abstract][Full Text] [Related]
32. [Hepatitis D screening is important in the Czech Republic as well].
Husa P; Snopková S; Husa P
Klin Mikrobiol Infekc Lek; 2021 Sep; 27(3):98-103. PubMed ID: 35170745
[TBL] [Abstract][Full Text] [Related]
33. Cell Culture Models for the Study of Hepatitis D Virus Entry and Infection.
Heuschkel MJ; Baumert TF; Verrier ER
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452397
[TBL] [Abstract][Full Text] [Related]
34. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.
Yan H; Zhong G; Xu G; He W; Jing Z; Gao Z; Huang Y; Qi Y; Peng B; Wang H; Fu L; Song M; Chen P; Gao W; Ren B; Sun Y; Cai T; Feng X; Sui J; Li W
Elife; 2012 Nov; 3():. PubMed ID: 25409679
[TBL] [Abstract][Full Text] [Related]
35. Entry Inhibitors of Hepatitis B and D Viruses.
Yang Y; Xie Y
Adv Exp Med Biol; 2022; 1366():199-205. PubMed ID: 35412142
[TBL] [Abstract][Full Text] [Related]
36. Innate immune recognition and modulation in hepatitis D virus infection.
Jung S; Altstetter SM; Protzer U
World J Gastroenterol; 2020 Jun; 26(21):2781-2791. PubMed ID: 32550754
[TBL] [Abstract][Full Text] [Related]
37. Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.
Liu H; Zakrzewicz D; Nosol K; Irobalieva RN; Mukherjee S; Bang-Sørensen R; Goldmann N; Kunz S; Rossi L; Kossiakoff AA; Urban S; Glebe D; Geyer J; Locher KP
Nat Commun; 2024 Mar; 15(1):2476. PubMed ID: 38509088
[TBL] [Abstract][Full Text] [Related]
38. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
[TBL] [Abstract][Full Text] [Related]
39. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
[TBL] [Abstract][Full Text] [Related]
40. Recent treatment advances and practical management of hepatitis D virus.
Olsen K; Mahgoub S; Al-Shakhshir S; Algieder A; Atabani S; Bannaga A; Elsharkawy AM
Clin Med (Lond); 2023 Jul; 23(4):403-408. PubMed ID: 37353306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]